Alexo Therapeutics is a clinical stage biotechnology company developing innovative immuno-oncology therapies for cancer. Alexo Therapeutics is a preclinical stage biotech company developing immuno-oncology therapies for cancer. Its goal is to develop immunotherapeutic adjuvants for use with broad combinations of antibodies to improve their therapeutic effectiveness.
ALX Oncology, Ltd.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttp://alxoncology.com
Founded2015
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address866 Malcolm Road, Suite 100,CA,94010CaliforniaUnited States
866 Malcolm Road, Suite 100,CA,94010
California
United States
Contact Number+1 650-466-7125
+1 650-466-7125
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/alexo-therapeutics” connections=”true” suffix=””]
Alexo Therapeutics proprietary candidates are fusion proteins that work in combination with anticancer antibodies to increase targeted phagocytosis, without carrying a pro-phagocytic signal to a variety of non-cancerous cells.
In May 2015, Alexo Therapeutics raised $36 Mn in Series A funding, which was led by venBio and joined by Lightstone Ventures, the Longevity Fund and Stanford University.